# PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer

> **NCT05732948** · PHASE1 · UNKNOWN · sponsor: **Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd** · enrollment: 12 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** autologous T cells & cyclophosphamide

## Key facts

- **NCT ID:** NCT05732948
- **Lead sponsor:** Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-02
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2023-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05732948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05732948, "PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05732948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*